tradingkey.logo
tradingkey.logo
Search

Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Nbip-'2118, A Corticotropin-Releasing Factor Type 2 Receptor Agonist

ReutersMay 4, 2026 11:37 AM
facebooktwitterlinkedin
View all comments0

- Neurocrine Biosciences Inc NBIX.O:

  • NEUROCRINE BIOSCIENCES ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY EVALUATING NBIP-'2118, A CORTICOTROPIN-RELEASING FACTOR TYPE 2 RECEPTOR AGONIST

  • NEUROCRINE BIOSCIENCES INC - INITIAL DATA FROM PHASE 1 NBIP-'2118 STUDY EXPECTED IN 2027

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI